Back to Search
MR. JOHN D KIRKWOOD DO
DO
Family Medicine Physician
NPI: 1073598777IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
J8017(TX)
Education
OKLAHOMA STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE
Class of 1993
Research & Publications (20)
Darwinian selection, selective breeding and the welfare of animals.
PMID 19234333·Vet Rec·2009
7-preclinical
Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors.
PMID 19499546·Int J Cancer·2009
8-other
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
PMID 19640287·J Transl Med·2009
3-trial
Liquid crystalline collagen: a self-assembled morphology for the orientation of mammalian cells.
PMID 19437784·Langmuir·2009
7-preclinical
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
PMID 19140204·Cancer·2009
3-trial
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
PMID 19380770·J Immunol·2009
8-other
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
PMID 19534815·J Transl Med·2009
8-other
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
PMID 19228745·Clin Cancer Res·2009
3-trial
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
PMID 19139427·J Clin Oncol·2009
3-trial
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
PMID 19349552·J Clin Oncol·2009
3-trial
Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
PMID 19364958·J Clin Oncol·2009
8-other
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008.
PMID 19659612·Pigment Cell Melanoma Res·2009
8-other
Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.
PMID 19047287·J Clin Oncol·2009
8-other
Highlights from the perspectives in melanoma XII conference.
PMID 19302131·Pigment Cell Melanoma Res·2009
7-preclinical
Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?
PMID 19092800·Nat Clin Pract Oncol·2009
8-other
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
PMID 18236459·Cancer·2008
6-review
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.
PMID 18286511·Cancer·2008
3-trial
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
PMID 18779741·J Immunother·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 5 locations total
- Address
- 3801 VISTA RD STE 100
PASADENA, TX 77504 - Phone
- (281) 249-2273
Locations (5)
Practice Location
3801 VISTA RD STE 100, PASADENA, TX
(281) 249-2273
Practice Location
4001 PRESTON AVE, PASADENA, TX
(281) 249-2251
Practice Location
600 N Kobayashi Ste 110, Webster, TX
(281) 338-1701
Practice Location
600 N KOBAYASHI STE 309, WEBSTER, TX
(281) 724-8332
Practice Location
500 N KOBAYASHI STE F, WEBSTER, TX
(281) 816-3092
Quick Facts
- NPI
- 1073598777
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 5
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile